Drugs / SHR8008
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05074602 | Sep 2021 → Sep 2023 | vulvovaginal candidiasis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04956419 | Apr → Sep 2021 | vulvovaginal candidiasis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-08-21 | Mycovia Pharmaceuticals Inc. | Regulatory Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China mycovia.com ↗
Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company, today announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) received approval in June from the National Medical Products Administration for Oteseconazole Capsules, an azole antifungal, indicated for the treatment of severe vulvovaginal candidiasis (VVC). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-08-21 | Mycovia Pharmaceuticals Inc. | Mycovia Pharmaceuticals, Inc. Announces Partner Jiangsu Hengrui Pharmaceuticals Co., Ltd’s Approval of Oteseconazole Capsules for the Treatment of Severe Vulvovaginal Candidiasis (VVC) in China mycovia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR8008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04956419 ↗ |
| Route | Oral | “once daily for 2 days(Day 1 and Day 2),oral” NCT04956419 ↗ |